Skip to search formSkip to main contentSkip to account menu

PF 00299804

Known as: PF-299804, EGFR Inhibitor PF-00299804, PF-00299804-03 
A highly selective, small-molecule inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase with potential antineoplastic activity… 
National Institutes of Health

Related topics

Related topics

2 relations

Broader (1)

Quinazolinones
dacomitinib

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2013
Review
2013
Rationale and study design of ARCHER: a randomized, double-blind, Phase III study of dacomitinib versus erlotinib for advanced non-small-cell lung cancer
Background: Dacomitinib (PF-00299804) is an irreversible pan-HER tyrosine kinase inhibitor. We describe the rationale and design… 
2012
2012
Abstract 2752: In vivo evaluation of dacomitinib (PF-00299804) in patient-derived salivary gland tumor models: Identification of a potential treatment options for adenoid cystic carcinoma
Proceedings: AACR 103rd Annual Meeting 2012‐‐ Mar 31‐Apr 4, 2012; Chicago, IL Adenoid cystic carcinoma (ACC) is an uncommon form… 
2011
2011
Pfizer and Qiagen Sign Second Companion Diagnostics Deal
Qiagen has signed a second companion diagnostics deal with Pfizer, this time to develop a molecular test for use with Pfizer’s… 
2010
2010
Phase (P) I study of PF-00299804 (PF) combined with figitumumab (FI; CP-751,871) in patients (pts) with advanced solid tumors (ASTs).
3026 Background: Cross-talk between human epidermal growth factor receptor (HER) and insulin-like growth factor type I receptor… 
2008
2008
Thérapies ciblées
2008
2008
Gateways to clinical trials. July-August 2008.
(-)-Epigallocatechin gallate, 501516, 89-12; Abatacept, Adalimumab, Adefovir dipivoxil, AG-701, Agatolimod sodium, Alefacept…